Clinical trial
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Evaluate the Efficacy and Safety of Petrelintide Co-Administered With RO7795068 in Adults With Obesity or Overweight
NCT07589686 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Evaluate the Efficacy and Safety of Petrelintide Co-Administered With RO7795068 in Adults With Obesity or Overweight
- Lead sponsor
- Hoffmann-La Roche
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- September 30, 2026
- Completion date
- January 31, 2028
- Enrollment
- 486 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
obesity or overweight